Related Experiment Video
Updated: Jan 8, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
[How I treat acquired clotting factor deficiency]
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
Acquired clotting factor deficiency encompasses bleeding disorders with diverse causes, including clotting factor inhibitors, liver disease, and disseminated intravascular coagulation. Among these, acquired clotting factor inhibitors are particularly rare and diagnostically challenging. Clinical management focuses on early recognition of bleeding, individualized therapy, and dynamic monitoring. In China, standardized protocols exist for acquired hemophilia A, while reports on other rare inhibitors are limited. Treatment strategies target both hemostasis and inhibitor eradication, with novel therapies for refractory cases. This article integrates clinical cases to provide practical guidance for standardized management.
Acquired clotting factor deficiency encompasses bleeding disorders with diverse causes, including clotting factor inhibitors, liver disease, and disseminated intravascular coagulation. Among these, acquired clotting factor inhibitors are particularly rare and diagnostically challenging. Clinical management focuses on early recognition of bleeding, individualized therapy, and dynamic monitoring. In China, standardized protocols exist for acquired hemophilia A, while reports on other rare inhibitors are limited. Treatment strategies target both hemostasis and inhibitor eradication, with novel therapies for refractory cases. This article integrates clinical cases to provide practical guidance for standardized management.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

